GeneralConnection.com ➔ Dictionary
Dictionary Search

nephropathy

Synonyms

Noun

1. kidney disease

2. renal disorder, nephrosis, uropathy

Usage
Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review - Pharmacy Times
Vertex says its drug successfully reduced marker of kidney disease in late-stage trial - statnews.com
Immunoglobulin A Nephropathy: 5 Treatment Approaches to Know - Medscape
Povetacicept Significantly Reduces Proteinuria in Adults With IgA Nephropathy - Medical Professionals Reference
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA - BioSpace
Vertex drug cuts proteinuria in Phase III IgA nephropathy trial - The Pharma Letter
KDIGO’s New IgA Nephropathy Guideline Is Paradigm-Shifting - Renal and Urology News
PLA2R, Membranous Nephropathy, and the PARASOL Membranous Project - HCPLive
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - Business Wire
Vertex eyes accelerated FDA nod for povetacicept with positive Phase III IgA nephropathy data - FirstWord Pharma
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy - The New England Journal of Medicine
Vertex kidney disease drug hits mark in late-stage study - BioPharma Dive
Are You Current with IgA Nephropathy Diagnosis Strategies? - MedCentral
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) - Novartis
IgA Nephropathy: Reviewing the Evidence on Current and Future Therapies - Cleveland Clinic
Reflux Nephropathy - UF Health - University of Florida Health
FDA Approval of Sibeprenlimab Signals New Era in IgA Nephropathy: Jackson Peter Kim, MD - AJMC
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - TradingView
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial - The New England Journal of Medicine
IgA Nephropathy: Reviewing the Evidence on Pathogenesis, Diagnosis and Prognosis - Cleveland Clinic
Vertex races to FDA after phase 3 kidney disease data impress analysts - Fierce Biotech
Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy - Quiver Quantitative
Unravelling the cause of a complex kidney disease - Nature
Primary Care for Kidney Failure Linked to Fewer ER Visits - Medscape
Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. - Barron's
Identifying and slowing diabetic nephropathy - Nebraska Medicine
Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy | Scientific Reports - Nature
5 Signs Your IgA Nephropathy May Be Getting Worse - Health: Trusted and Empathetic Health and Wellness Information
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise - simplywall.st
The Incidence of Contrast-Induced Nephropathy Following Computed Tomography and Associated Risk Factors - Wiley Online Library
Licorice in nephropathy treatment: phytochemical compositions and pharmacological mechanisms - Frontiers
‘Missing’ disease-causing variants in Alport syndrome - Nature
RAINIER: Povetacicept Reduces Proteinuria By 52.0% - HCPLive
Can IgA Nephropathy Be Reversed? - Health: Trusted and Empathetic Health and Wellness Information
IgA nephropathy with crescent cell lesions in a human brucellosis patient: a case report - Frontiers
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making - AJMC
Capilliposide A attenuates diabetic nephropathy via modulation of NF-κB/TLR4 and apoptotic pathways - Nature
A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus - The ASCO Post
Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice - Frontiers
Discovery of non-invasive biomarkers for accurate detection of membranous nephropathy - Nature
Alport syndrome complicated with IgA nephropathy: a case report - Frontiers
TGFβ1 accelerated the progression of diabetic nephropathy via up-regulating BRD4/Notch1/YAP signaling induced fibrosis and proliferation in fibroblasts - Nature
Understanding kidney health: What South Africans need to know - eNCA
Gut microbiota dysbiosis in diabetic nephropathy: mechanisms and therapeutic targeting via the gut-kidney axis - Frontiers
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug - Investor's Business Daily
Acupuncture for diabetic nephropathy: mechanisms, clinical evidence, and future perspectives - Frontiers
Vertex's $4.9B kidney disease bet hits key milestone - The Business Journals
What We Know About Treatments for Berger’s Disease - Health: Trusted and Empathetic Health and Wellness Information
Evidence-Based Therapies Targeting the Heterogeneity of IgA Nephropathy - AJMC
Fermented seaweed extracts ameliorate diabetic nephropathy in streptozotocin-induced diabetic rats via PI3K/AKT/mTOR pathway - Nature
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition - MedCity News
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study - Finviz
Inflammation-associated molecules in the glomerular-endothelium in mild IgA-nephropathy patients identified by single-cell and spatial transcriptome | Communications Biology - Nature
Hypertensive Nephrosclerosis: Pathological Changes and Overlap with Diabetic Nephropathy - Cureus
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally - FinancialContent
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints i - PharmiWeb.com
Diabetic nephropathy with minimal change disease: a case report - Frontiers
Isolated Antiphospholipid Syndrome Nephropathy (aPL Nephropathy)—A Rare Cause of a Rapid Decline in Kidney Function in a Patient With Systemic Lupus Erhythematosus - Wiley Online Library
Opportunities and challenges in the treatment of IgA nephropathy - Frontiers
Immunomodulatory roles of quercetin in diabetic nephropathy: targeting inflammation, oxidative stress, and ferroptosis - Frontiers
World Kidney Day | How heat dehydration and pollution are impacting kidney health in India - theweek.in
How IgA Nephropathy Is Diagnosed: Step-by-Step - Verywell Health
IgA Nephropathy With Membranoproliferative Pattern and Resistance to Immunosuppressive Therapy in Two Patients With Cofactor I Pathogenic Variant - Wiley Online Library
Development and preliminary validation of a predictive model for IgA nephropathy progression - Nature
Adriamycin nephropathy induces sensorineural hearing loss via blood–labyrinth barrier breakdown in BALB/c mice - Nature
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) - Novartis
Rapid diagnosis of membranous nephropathy based on kidney tissue Raman spectroscopy and deep learning - Nature
Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization - Wiley
IgA Nephropathy Market Hits US$ 500.3 Billion By 2033 - Market.us Media
Exploring genotype-phenotype correlation in nucleoporin nephropathy - Nature
Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review - Frontiers
IgA Nephropathy and End Stage Renal Disease - Healthline
Vertex Pharmaceuticals (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results - Blockonomi
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy - The New England Journal of Medicine
Vertex Pharmaceuticals (VRTX) Stock Rises 5% on Kidney Drug Trial Win - CoinCentral
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy - The New England Journal of Medicine
Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series - Nature
NELL1 membranous nephropathy: clinical associations provide mechanistic clues - Frontiers
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy - Nature
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy - The New England Journal of Medicine
The nephropathy of sickle cell trait and sickle cell disease - Nature
Machine learning-based diagnostic prediction of IgA nephropathy: model development and validation study - Nature
The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis - Nature
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies - Frontiers
A multimodal transformer system for noninvasive diabetic nephropathy diagnosis via retinal imaging - Nature
Personalized contrast agent dosing to prevent contrast induced nephropathy in high risk populations in Guangdong, China - Nature
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet
CBGA ameliorates inflammation and fibrosis in nephropathy - Scientific Reports - Nature
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes - The New England Journal of Medicine
Nicotine, smoking, podocytes, and diabetic nephropathy - American Physiological Society Journal
Identification of key candidate genes for IgA nephropathy using machine learning and statistics based bioinformatics models - Nature
Early renal structural changes and potential biomarkers in diabetic nephropathy - Frontiers
Urinary exosomal miRNA signature of IgA nephropathy: a case–control study - Nature
IgA Nephropathy | New England Journal of Medicine - The New England Journal of Medicine
Therapy of IgA nephropathy: time for a paradigm change - Frontiers
Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome - Nature
The pathogenesis of IgA nephropathy and implications for treatment - Nature
Diabetic Kidney Disease - National Institutes of Health (.gov)
The impact of metabolic component count on IgA nephropathy prognosis - Nature
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy - The New England Journal of Medicine
Foreign Language Equivalents
Foreign Language Equivalents of 'nephropathy'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
neohropathy,   nephroopathy,   nephrropathy,   nephroparhy,   bephropathy,   ne[hropathy,   nephroathy,   nephopathy,   nephropathhy,   nrphropathy,   mephropathy,   nehpropathy,   nephrooathy,   nepheopathy,   nepjropathy,   nephropatthy,   nephropsthy,   nephroppathy,   neprhopathy,   nephroptahy,   nephripathy,   nephropath,   nephroapthy,   npehropathy,   nephropatyh,   nephtopathy,   nephrpathy,   nephrppathy,   nehropathy,   nephropatjy,   nephropaathy,   nephropatgy,   nphropathy,   nephropahty,   nephropaty,   ephropathy,   enphropathy,   nephropahy,   nephropthy,   nephropathyy,   nephro[athy,   nnephropathy,   nephropatht,   nephorpathy,   nepgropathy,   nephhropathy,   nephrpoathy,   nephropayhy,   nepropathy,   nepphropathy,   nephropathu,   neephropathy,   nwphropathy
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z